Sihuan Pharmaceutical Projects Revenue of Over RMB1,100 Million and Net Profit Exceeding RMB50 Million for H1 2025

Reuters

08/01

Sihuan Pharmaceutical Projects Revenue of Over RMB1,100 Million and Net Profit Exceeding RMB50 Million for H1 2025

Sihuan Pharmaceutical Holdings Group Ltd. has issued a positive profit alert, indicating an optimistic financial outlook for the first half of 2025. The company expects to record a revenue of not less than RMB1,100 million and a net profit of not less than RMB50 million for the period ending June 30, 2025. This growth is attributed to the successful launch of significant new products, including the Insulin Degludec and Insulin Aspart Injection, branded as Huiyoujia®, and the Insulin Degludec Injection, branded as Huiyouda®. These products are anticipated to drive strong momentum for future revenue and profit growth. The detailed financial results will be disclosed in the interim results announcement, expected to be published before the end of August 2025. Shareholders and potential investors are advised to exercise caution as the information has not been audited and may be subject to adjustments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Holdings Group Ltd. published the original content used to generate this news brief on August 01, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2556581145"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556581145\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556581145?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-01 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556581145","market":"us","top_or_hot":-1,"title":"Sihuan Pharmaceutical Projects Revenue of Over RMB1,100 Million and Net Profit Exceeding RMB50 Million for H1 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sihuan Pharmaceutical Projects Revenue of Over RMB1,100 Million and Net Profit Exceeding RMB50 Million for H1 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SHPHF\">Sihuan Pharmaceutical Holdings Group Ltd.</a> has issued a positive profit alert, indicating an optimistic financial outlook for the first half of 2025. The company expects to record a revenue of not less than RMB1,100 million and a net profit of not less than RMB50 million for the period ending June 30, 2025. This growth is attributed to the successful launch of significant new products, including the Insulin Degludec and Insulin Aspart Injection, branded as Huiyoujia®, and the Insulin Degludec Injection, branded as Huiyouda®. These products are anticipated to drive strong momentum for future revenue and profit growth. The detailed financial results will be disclosed in the interim results announcement, expected to be published before the end of August 2025. Shareholders and potential investors are advised to exercise caution as the information has not been audited and may be subject to adjustments.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SHPHY\">Sihuan Pharmaceutical Holdings Group Ltd.</a> published the original content used to generate this news brief on August 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sihuan Pharmaceutical Projects Revenue of Over RMB1,100 Million and Net Profit Exceeding RMB50 Million for H1 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSihuan Pharmaceutical Projects Revenue of Over RMB1,100 Million and Net Profit Exceeding RMB50 Million for H1 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-01 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sihuan Pharmaceutical Projects Revenue of Over RMB1,100 Million and Net Profit Exceeding RMB50 Million for H1 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SHPHF\">Sihuan Pharmaceutical Holdings Group Ltd.</a> has issued a positive profit alert, indicating an optimistic financial outlook for the first half of 2025. The company expects to record a revenue of not less than RMB1,100 million and a net profit of not less than RMB50 million for the period ending June 30, 2025. This growth is attributed to the successful launch of significant new products, including the Insulin Degludec and Insulin Aspart Injection, branded as Huiyoujia®, and the Insulin Degludec Injection, branded as Huiyouda®. These products are anticipated to drive strong momentum for future revenue and profit growth. The detailed financial results will be disclosed in the interim results announcement, expected to be published before the end of August 2025. Shareholders and potential investors are advised to exercise caution as the information has not been audited and may be subject to adjustments.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SHPHY\">Sihuan Pharmaceutical Holdings Group Ltd.</a> published the original content used to generate this news brief on August 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00460","symbol_name":"四环医药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250801:nNDL5ZQJh2:1","article_id":"2556581145","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556581145","pubTimestamp":1754056861,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sihuan Pharmaceutical Holdings Group Ltd. has issued a positive profit alert, indicating an optimistic financial outlook for the first half of 2025. The company expects to record a revenue of not less than RMB1,100 million and a net profit of not less than RMB50 million for the period ending June 30, 2025. This growth is attributed to the successful launch of significant new products, including the Insulin Degludec and Insulin Aspart Injection, branded as Huiyoujia, and the Insulin Degludec Injection, branded as Huiyouda. These products are anticipated to drive strong momentum for future revenue and profit growth. The detailed financial results will be disclosed in the interim results announcement, expected to be published before the end of August 2025. Shareholders and potential investors are advised to exercise caution as the information has not been audited and may be subject to adjustments.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"00460":"四环医药"},"translate_title":"四环医药预计2025年上半年营收超11亿元，净利润超5000万元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":0.9},"content_text":"Sihuan Pharmaceutical Projects Revenue of Over RMB1,100 Million and Net Profit Exceeding RMB50 Million for H1 2025\n    \n\nSihuan Pharmaceutical Holdings Group Ltd. has issued a positive profit alert, indicating an optimistic financial outlook for the first half of 2025. The company expects to record a revenue of not less than RMB1,100 million and a net profit of not less than RMB50 million for the period ending June 30, 2025. This growth is attributed to the successful launch of significant new products, including the Insulin Degludec and Insulin Aspart Injection, branded as Huiyoujia®, and the Insulin Degludec Injection, branded as Huiyouda®. These products are anticipated to drive strong momentum for future revenue and profit growth. The detailed financial results will be disclosed in the interim results announcement, expected to be published before the end of August 2025. Shareholders and potential investors are advised to exercise caution as the information has not been audited and may be subject to adjustments.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Holdings Group Ltd. published the original content used to generate this news brief on August 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}